查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1445530

全球導管相關血流感染(CRBSI)市場評估：按藥物類別、治療、來源、分銷管道和地區劃分的機會和預測（2017-2031年）

Catheter-Related Bloodstream Infection Market Assessment, By Drug Class, By Treatment, By Source of Infection, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 232 Pages | 商品交期: 3-5個工作天內

價格

全球導管相關血流感染 (CRBSI) 市場規模將從 2023 年的 17.1 億美元增長到 2031 年的 25 億美元，2024-2031 年預測期間複合年增長率為 5.35%。預計將增長到9000萬美元。

市場成長的驅動因素是世界不同地區侵入性醫療程序數量的增加、人口老化的加劇、慢性病盛行率的增加。

越來越多地採用先進產品和技術（例如增強型診斷方法和抗菌塗層導管）來預防和治療 CRBSI，為市場提供了利潤豐厚的成長機會。 CRBSI 的長期挑戰是推動尖端解決方案的開發。 不當的滅菌方法和不斷增加的醫院感染盛行率是推動市場需求的一些主要因素。 研究機構和主要參與者越來越關注開發促進患者安全的先進產品，這進一步支持了市場擴張。

增加與 CRBSI 相關的研究活動

正在進行各種研究活動和調查，以了解與這種疾病相關的各種併發症並追蹤 CRBSI 並最終減少病例數。 2023年，在加納一家三級醫院進行的一項橫斷面研究發表，旨在確定維持性血液透析患者中□□與CRBSI相關的因素，觀察到CRBSI的盛行率很高。

參與公司加強開發新療法

各個主要參與者正在努力開發 CRBSI 的治療和預防解決方案。 2023 年，CorMedix, Inc. 的 DefenCath 獲得 FDA 批准。 這種含有肝素和牛磺羅定的導管封管溶液有助於治療和預防接受中心靜脈導管慢性血液透析的成人的 CRBSI。 DefenCath 是水性、無菌、透明且不含防腐劑的，是美國核准的第一個也是唯一一個抗菌封管液。

北美佔較大市佔率

該地區的市場擴張是由於老年人口的不斷增長、導管插入術的需求不斷增加、醫療基礎設施的完善以及血液相關感染治療技術的快速進步。 根據人口參考局的數據，從 2022 年到 2050 年，65 歲及以上的美國人數量預計將增加 47%。 預計這一數字將從5,800萬人（2022年）增加到8,200萬人（2050年），65歲及以上人口比例預計將從17%增加到23%。

本報告調查了全球導管相關血流感染(CRBSI) 市場，並提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構和市場成長。它總結了影響因素的分析因素、案例研究、競爭格局和主要公司概況。

目錄

第 1 章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第 4 章全球導管相關血流感染 (CRBSI) 市場展望

  • 市場規模/預測
  • 依藥物類別
    • 頭孢唑林
    • 萬古黴素
    • 氯唑西林
    • 達托黴素
    • 其他
  • 依治療方法
    • 抗生素封閉療法
    • 抗菌劑
  • 依感染源分類
    • 凝固□陰性葡萄球菌
    • 酵母
    • 假單胞菌屬。
    • 金黃色葡萄球菌
    • 腸球菌/鏈球菌
    • 腸道革蘭氏陰性桿菌
    • 其他
  • 按分銷管道
    • 醫院藥房
    • 零售藥局
    • 網路藥局
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 各公司的市佔率

第 5 章按地區劃分的全球導管相關血流感染 (CRBSI) 市場展望

  • 北美
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東/非洲

第 6 章市場映射

  • 依藥物類別
  • 透過治療
  • 依感染源分類
  • 按分銷管道
  • 按地區

第 7 章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 生長抑制因素（問題、限制因素）

第 9 章監理架構與創新

  • 臨床試驗
  • 專利情況
  • 監理機關的核准
  • 創新/新興技術

第 10 章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析
  • 併購/合資企業（如果適用）
  • SWOT 分析（5 家參與公司）
  • 專利分析（如果適用）

第 11 章價格分析

第 12 章案例研究

第 13 章主要公司展望

  • Pfizer, Inc.
  • Citius Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Geistlich Pharma AG
  • CorMedix, Inc.
  • TauroPharm GmbH
  • Fresenius SE & Co. KGaA
  • Novartis AG
  • Teva Pharmaceuticals
  • Eli Lilly and Company

第 14 章策略建議

第 15 章關於我們公司/免責聲明

Product Code: MX11079

Global catheter-related bloodstream infection market is projected to witness a CAGR of 5.35% during the forecast period 2024-2031, growing from USD 1.71 billion in 2023 to USD 2.59 billion in 2031F. The market growth is driven by a rise in the number of invasive medical procedures, an increasing aging population, and a growing prevalence of chronic diseases in various regions across the globe.

The rising adoption of advanced products and technologies for the prevention and treatment of catheter-related bloodstream infections, including enhanced diagnostic methods and antimicrobial-coated catheters, is providing lucrative growth opportunities for the market. The long-posed challenges of catheter-related bloodstream infections are prompting the development of cutting-edge solutions. The increasing incidence related to improper aseptic procedures and the growing prevalence of hospital-acquired infections are some of the major factors bolstering the market demand. The increasing emphasis of research organizations and major market players on the development of advanced products that promote patient safety is further supporting the market expansion.

According to a ScienceDirect article, in the Elsevier Journal in December 2023, a team of researchers and The Flume Catheter Company, in the United Kingdom is working on the development and testing of a FLUME urinary catheter with relocated drainage holes and protected tip. The retaining balloon supports a static load of 700 grams and reduced trauma when forced evulsion was modeled. The catheter design aims to enhance patient safety and comfort while maximizing bladder drainage.

Increasing Research Activities on CRBSI

Various research activities and studies are being conducted to understand the different complications associated with the disease and track CRBSI to ultimately reduce the number of cases. In 2023, a cross-sectional study conducted at a tertiary hospital in Ghana to determine the factors associated with catheter-related bloodstream infections among patients who were on maintenance hemodialysis was published. The cross-sectional hospital-based study was conducted on patients who were receiving maintenance hemodialysis via central venous catheters. The risk factors that were predictive of catheter-related bloodstream infections were determined with the help of multivariate analysis using logistic regression. High prevalence of catheter-related bloodstream infections was noted among patients undergoing hemodialysis. The most common causative agent was Coagulase negative Staphylococci. As per the conclusion of the study, there is a high requirement for infection surveillance units in the renal unit for tracking catheter-related bloodstream infections and taking significant measures to reduce these infections. It was noted that the prevalence of catheter-related bloodstream infections among the participants was 34.2%. A contributing factor for the prevalence of CRBSI in the participants of the study may be the lack of utilization of antiseptic or antibiotic lock system.

Increasing Efforts Towards Development of Novel Treatments by Market Players

Various major market players are dedicated towards developing treatment and prevention solutions for catheter-related bloodstream infections. In 2023, CorMedix, Inc. received FDA approval for DefenCath. The heparin and taurolidine containing catheter lock solution aids in treating and preventing catheter-related bloodstream infections in adults undergoing chronic hemodialysis through a central venous catheter. The aqueous-based, sterile, clear, and preservative-free DefenCath is the first and only antimicrobial catheter lock solution approved in the United States. DefenCath will allow healthcare providers to reduce the risk of infections in patients suffering from underlying kidney failure. The approval of the product was based upon the findings from the Phase 3 LOCK-IT-100 clinical study. The multicentral, randomized, active control, double-blind trial analyzed the safety and efficacy of DefenCath in lowering the incidences of catheter-related bloodstream infections in patients undergoing chronic hemodialysis due to kidney failure.

North America Accounts for a Significant Market Share

The expansion of the market in the region can be attributed to the growth of the geriatric population, increased requirement for catheters insertion, presence of a well-established healthcare infrastructure and rapid technological advancements for treatment of blood related infections. According to the Population Reference Bureau, the number of Americans aging 65 years and older is estimated to witness a 47% increase from 2022 to 2050. The number is projected to increase from 58 million (in 2022) to 82 million (by 2050). The share of the 65-and-older age group is expected to increase from 17% to 23%.

Frequent catheterization is often required in the elderly if they are suffering from urinary retention, continence, cancer, and pressure ulcers, increasing the risk of catheter-related bloodstream infections. Long-term catheterization is preferred by various caretakers and healthcare professionals as it reduces their burden and allows them to focus on the other requirements of the patient. However, catheterization for long intervals of time can often lead to complications and cause catheter-related bloodstream infections.

Increasing Research Activities on Coagulase-Negative Staphylococcus Support Segment Growth

Undergoing research activities are expected to determine how to effectively manage catheter-related bloodstream infection caused by coagulase-negative staphylococcus. As per the clinical guidelines, the management of coagulase-negative staphylococcus causing catheter-related bloodstream infections requires antibiotic treatment for five to seven days along with catheter removal. According to an Antibiotics article published in May 2023, in National Library of Medicine, randomized clinical trials are being conducted with the aim to determine whether no administration of antibiotic therapy is effective and safe in low-risk episodes of catheter-related bloodstream infections caused by coagulase-negative staphylococcus. In the study, the patients suffering from CRBSI caused by coagulase-negative staphylococcus were randomized 1:1 after the withdrawal of catheter were opted to receive or not receive parenteral antibiotics that act against the isolated strain. The secondary endpoints of the study were septic embolism, persistent bacteremia, time until the disappearance of the fever, and time until microbiological cure. The primary endpoint was the occurrence of any complications related to the antibiotic therapy or bacteremia within the ninety days of the follow-up.

Online Pharmacies Expected to Witness Significant Growth Over the Forecast Period

Owing to the convenience offered by online pharmacies, including fast deliveries, this distribution channel has evolved from an alternative method for procuring medication and has gained immense popularity. Over the past few years more patients have recognized the convenient nature of shopping across these pharmacies, supplanting the reliance on retail pharmacies. According to a survey funded by Sanofi Consumer Healthcare, respondents indicated various advantages of online pharmacies including reduced costs for patients, convenience, and increased access for patients.

Online pharmacies eliminate the requirement of calling in a prescription, walking or driving to the pharmacy and waiting in line. The unparalleled levels of confidentiality and privacy offered by online pharmacies is further boosting the popularity of the distribution channel. The growth of the segment is facilitated by the rapid expansion of the internet services and ease of mail-order trade. Furthermore, the price transparency and accessibility offered by online pharmacies is encouraging consumers to adopt these channels for purchasing different medication.

Future Market Scenario (2024 - 2031F)

The catheter-related bloodstream infection (CRBSI) market is expected to witness significant growth in the coming years due to several factors including increasing emphasis on research and development activities and growing requirement for catheters in elderly patients.

The rising investments towards the healthcare and pharmaceutical industries is expected to offer lucrative growth opportunities to the market.

Various studies are being conducted to examine the risk of catheter-related bloodstream infections in patients with hemodialysis catheters. For instance, Zealand University Hospital is conducting an interventional study to examine the effects of ethanol (70%) as a lock solution. The study is estimated to conclude in April 2025.

University of Zurich is on the phase 4 of their interventional study aiming to understand the effect of vancomycin after catheter replacement. The randomized controlled trial will study the effect of a single dose of vancomycin on infection resolution after the replacement of catheter for suspected central line-associated bloodstream infection. The study is expected to conclude in December 2024.

Key Players Landscape and Outlook

Key participants in the catheter-related bloodstream infection market include Pfizer Inc., Citius Pharmaceuticals, Inc., Glenmark Pharmaceuticals Ltd., CorMedix, Inc., and Teva Pharmaceuticals. Increasing research and development activities and strategic partnerships between leading market players is expected to offer lucrative growth opportunities to the market.

In 2023, CorMedix, Inc. received FDA approval for DefenCath. According to FDA, the drug will reduce incidences of catheter-related bloodstream infections in adults receiving chronic hemodialysis via a central catheter due to kidney failure.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Catheter-Related Bloodstream Infection Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Drug Class
    • 4.2.1. Cefazoline
    • 4.2.2. Vancomycin
    • 4.2.3. Cloxacillin
    • 4.2.4. Daptomycin
    • 4.2.5. Others
  • 4.3. By Treatment
    • 4.3.1. Antibiotic Lock Therapy
    • 4.3.2. Anti-microbial Agents
  • 4.4. By Source of Infection
    • 4.4.1. Coagulase-Negative Staphylococcus
    • 4.4.2. Yeast
    • 4.4.3. Pseudomonas
    • 4.4.4. S. aureus
    • 4.4.5. Enterococci and Streptococci
    • 4.4.6. Enteric Gram-negative Bacilli
    • 4.4.7. Others
  • 4.5. By Distribution Channel
    • 4.5.1. Hospital Pharmacies
    • 4.5.2. Retail Pharmacies
    • 4.5.3. Online Pharmacies
  • 4.6. By Region
    • 4.6.1. North America
    • 4.6.2. South America
    • 4.6.3. Europe
    • 4.6.4. Asia-Pacific
    • 4.6.5. Middle East & Africa
  • 4.7. By Company Market Share (%), 2023

5. Global Catheter-Related Bloodstream Infection Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Drug Class
      • 5.1.2.1. Cefazoline
      • 5.1.2.2. Vancomycin
      • 5.1.2.3. Cloxacillin
      • 5.1.2.4. Daptomycin
      • 5.1.2.5. Others
    • 5.1.3. By Treatment
      • 5.1.3.1. Antibiotic Lock Therapy
      • 5.1.3.2. Anti-microbial Agents
    • 5.1.4. By Source of Infection
      • 5.1.4.1. Coagulase-Negative Staphylococcus
      • 5.1.4.2. Yeast
      • 5.1.4.3. Pseudomonas
      • 5.1.4.4. S. aureus
      • 5.1.4.5. Enterococci and Streptococci
      • 5.1.4.6. Enteric Gram-negative Bacilli
      • 5.1.4.7. Others
    • 5.1.5. By Distribution Channel
      • 5.1.5.1. Hospital Pharmacies
      • 5.1.5.2. Retail Pharmacies
      • 5.1.5.3. Online Pharmacies
    • 5.1.6. United States*
      • 5.1.6.1. Market Size & Forecast
      • 5.1.6.1.1. By Value
      • 5.1.6.1.2. By Volume
      • 5.1.6.2. By Drug Class
      • 5.1.6.2.1. Cefazoline
      • 5.1.6.2.2. Vancomycin
      • 5.1.6.2.3. Cloxacillin
      • 5.1.6.2.4. Daptomycin
      • 5.1.6.2.5. Others
      • 5.1.6.3. By Treatment
      • 5.1.6.3.1. Antibiotic Lock Therapy
      • 5.1.6.3.2. Anti-microbial Agents
      • 5.1.6.4. By Source of Infection
      • 5.1.6.4.1. Coagulase-Negative Staphylococcus
      • 5.1.6.4.2. Yeast
      • 5.1.6.4.3. Pseudomonas
      • 5.1.6.4.4. S. aureus
      • 5.1.6.4.5. Enterococci and Streptococci
      • 5.1.6.4.6. Enteric Gram-negative Bacilli
      • 5.1.6.4.7. Others
      • 5.1.6.5. By Distribution Channel
      • 5.1.6.5.1. Hospital Pharmacies
      • 5.1.6.5.2. Retail Pharmacies
      • 5.1.6.5.3. Online Pharmacies
    • 5.1.7. Canada
    • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Drug Class
  • 6.2. By Treatment
  • 6.3. By Source of Infection
  • 6.4. By Distribution Channel
  • 6.5. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Pfizer, Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Citius Pharmaceuticals, Inc.
  • 13.3. Glenmark Pharmaceuticals Ltd.
  • 13.4. Geistlich Pharma AG
  • 13.5. CorMedix, Inc.
  • 13.6. TauroPharm GmbH
  • 13.7. Fresenius SE & Co. KGaA
  • 13.8. Novartis AG
  • 13.9. Teva Pharmaceuticals
  • 13.10. Eli Lilly and Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 4. Global Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 5. Global Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 6. Global Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 7. Global Catheter-Related Bloodstream Infection Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 10. North America Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 11. North America Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 12. North America Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 13. North America Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 14. North America Catheter-Related Bloodstream Infection Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 17. United States Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 18. United States Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 19. United States Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 20. United States Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 21. Canada Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 23. Canada Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 24. Canada Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 25. Canada Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 26. Canada Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 27. Mexico Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 29. Mexico Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 30. Mexico Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 31. Mexico Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 32. Mexico Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 33. Europe Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 35. Europe Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 36. Europe Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 37. Europe Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 38. Europe Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 39. Europe Catheter-Related Bloodstream Infection Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 42. Germany Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 43. Germany Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 44. Germany Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 45. Germany Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 46. France Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 48. France Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 49. France Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 50. France Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 51. France Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 52. Italy Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 54. Italy Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 55. Italy Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 56. Italy Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 57. Italy Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 58. United Kingdom Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 60. United Kingdom Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 61. United Kingdom Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 62. United Kingdom Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 63. United Kingdom Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 64. Russia Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 66. Russia Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 67. Russia Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 68. Russia Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 69. Russia Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 70. Netherlands Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 72. Netherlands Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 73. Netherlands Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 74. Netherlands Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 75. Netherlands Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 76. Spain Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 78. Spain Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 79. Spain Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 80. Spain Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 81. Spain Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 82. Turkey Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 84. Turkey Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 85. Turkey Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 86. Turkey Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 87. Turkey Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 88. Poland Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 90. Poland Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 91. Poland Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 92. Poland Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 93. Poland Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 94. South America Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 96. South America Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 97. South America Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 98. South America Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 99. South America Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 100. South America Catheter-Related Bloodstream Infection Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 103. Brazil Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 104. Brazil Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 105. Brazil Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 106. Brazil Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 107. Argentina Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 109. Argentina Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 110. Argentina Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 111. Argentina Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 112. Argentina Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 113. Asia-Pacific Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 115. Asia-Pacific Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 116. Asia-Pacific Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 117. Asia-Pacific Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 118. Asia-Pacific Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 119. Asia-Pacific Catheter-Related Bloodstream Infection Market Share (%), By Country, 2017-2031F
  • Figure 120. India Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 122. India Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 123. India Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 124. India Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 125. India Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 126. China Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 128. China Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 129. China Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 130. China Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 131. China Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 132. Japan Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 134. Japan Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 135. Japan Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 136. Japan Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 137. Japan Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 138. Australia Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 140. Australia Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 141. Australia Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 142. Australia Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 143. Australia Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 144. Vietnam Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 146. Vietnam Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 147. Vietnam Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 148. Vietnam Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 149. Vietnam Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 150. South Korea Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 152. South Korea Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 153. South Korea Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 154. South Korea Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 155. South Korea Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 156. Indonesia Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 158. Indonesia Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 159. Indonesia Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 160. Indonesia Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 161. Indonesia Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 162. Philippines Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 164. Philippines Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 165. Philippines Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 166. Philippines Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 167. Philippines Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 168. Middle East & Africa Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 170. Middle East & Africa Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 171. Middle East & Africa Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 172. Middle East & Africa Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 173. Middle East & Africa Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 174. Middle East & Africa Catheter-Related Bloodstream Infection Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 177. Saudi Arabia Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 178. Saudi Arabia Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 179. Saudi Arabia Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 180. Saudi Arabia Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 181. UAE Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 183. UAE Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 184. UAE Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 185. UAE Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 186. UAE Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 187. South Africa Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
  • Figure 189. South Africa Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
  • Figure 190. South Africa Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
  • Figure 191. South Africa Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
  • Figure 192. South Africa Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 193. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Source of Infection Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023